Leveraging ProPhase Labs’ AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development.
Antibody drug conjugates (ADCs) are specialized treatments that differ from traditional chemotherapy by specifically targeting cancer cells. ADCs use a linker to attach chemotherapy agents to a monoclonal antibody, which then binds to a unique marker found on the surface of cancer cells. This targeted approach helps to minimize damage to healthy cells and other side effects. ADCs represent a potent class of cancer therapies, blending the specificity of monoclonal antibodies with cytotoxic drugs. Leveraging ZenQ-AI with both genomic and proteomic data is believed to enable the rapid identification of biomarkers and mutations driving cancer, streamlining the design of ADCs for precise targeting. This integration promises more effective and personalized treatments, though rigorous experimental validation remains crucial for ensuring safety and efficacy of new therapeutic candidates.
"The power of Project ZenQ-AI not only stems from cutting-edge AI technology, but also the vast and growing genomic database that we’ve curated and continue to grow," explained
Decoding the Genomic Advantage: WGS over Ancestry SNP-Based Tests
Central to Project ZenQ-AI's innovative approach is the utilization of whole genome sequencing, and its comprehensive method of examining all 3 billion base pairs of the human genome. This provides a much greater advantage in exploring genomic changes than ancestry SNP-based tests, which only look at mutations in specific points in the genome. WGS provides more of a complete picture, offering in-depth insights into genetic factors influencing diseases and treatment responses.
Leveraging Advanced Technologies for Enhanced Capabilities
To support the computational demands of Project ZenQ-AI,
BE-Smart: Six Years in the Making
The BE-Smart initiative, now integrated into Project ZenQ-AI, has been in development for over six years. It focuses on harnessing a detailed and patented proteomic database to better understand EAC and its early detection. EAC is one of the deadliest cancers and currently has no effective targeted treatment options. Currently, roughly 80-90% of those diagnosed ultimately lose their battle to EAC. “Our research has yielded several patented protein targets that have not been previously explored by the medical community,” stated
Nebula Genomics: A Global Perspective
The global diversity of Nebula’s data base greatly enriches the value of the data and enhances Project ZenQ-AI's development of algorithms, thereby allowing the identification of unique genetic markers and therapeutic targets across diverse populations and enhancing the breadth and effectiveness of ADC treatments. The Company believes that Project ZenQ-AI represents the forefront of AI-driven research in ADC development. By combining the extensive WGS database of Nebula Genomics with the specialized insights from the BE-Smart Cancer Test, the Company believes that Project ZenQ-AI is set to invigorate the field of identification of novel, actionable targets for cancer therapies.
Beyond EAC: The Future of Oncology
While initially focusing on early diagnosis of EAC, the implications of Project ZenQ-AI extend far beyond. The platform sets a new milestone for ProPhase, offering the promise of more effective, and less toxic cancer treatments across a variety of cancer types.
"This initiative represents an important advancement for our Company, as it integrates the extensive development and expertise of our subsidiaries, Nebula Genomics and ProPhase BioPharma, to lead breakthroughs in precision oncology," added
Join Us on the Journey
About
Forward-Looking Statements
Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our plans to grow our subsidiaries and build a multi-billion dollar company, our expected timeline for commercializing our BE-Smart Test and its market potential and our belief in Project ZenQ-AI's potential to contribute to the identification of novel, actionable targets for cancer therapies. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other
ProPhase Media Relations and Institutional Investor Contact:
267-880-1111
investorrelations@prophaselabs.com
ProPhase Retail Investor Relations Contact:
514-939-3989
Jboidman@renmarkfinancial.com
Source:
Source:
2024 GlobeNewswire, Inc., source